Cargando…

Integrative Evaluation of the Clinical Significance Underlying Protein Arginine Methyltransferases in Hepatocellular Carcinoma

SIMPLE SUMMARY: Protein arginine methyltransferases (PRMTs) are a group of enzymes that play pivotal roles in post-translational modifications (PTMs) and are involved in the regulation of various cellular processes. Although PRMTs are recognized for their impact on the development and prognosis of v...

Descripción completa

Detalles Bibliográficos
Autores principales: Jiang, Yikun, Wei, Shibo, Koo, Jin-Mo, Kim, Hea-Ju, Park, Wonyoung, Zhang, Yan, Guo, He, Ha, Ki-Tae, Oh, Chang-Myung, Kang, Jong-Sun, Jeong, Jee-Heon, Ryu, Dongryeol, Kim, Kyeong-Jin, Jo, Yunju
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10453297/
https://www.ncbi.nlm.nih.gov/pubmed/37627211
http://dx.doi.org/10.3390/cancers15164183
_version_ 1785095900729704448
author Jiang, Yikun
Wei, Shibo
Koo, Jin-Mo
Kim, Hea-Ju
Park, Wonyoung
Zhang, Yan
Guo, He
Ha, Ki-Tae
Oh, Chang-Myung
Kang, Jong-Sun
Jeong, Jee-Heon
Ryu, Dongryeol
Kim, Kyeong-Jin
Jo, Yunju
author_facet Jiang, Yikun
Wei, Shibo
Koo, Jin-Mo
Kim, Hea-Ju
Park, Wonyoung
Zhang, Yan
Guo, He
Ha, Ki-Tae
Oh, Chang-Myung
Kang, Jong-Sun
Jeong, Jee-Heon
Ryu, Dongryeol
Kim, Kyeong-Jin
Jo, Yunju
author_sort Jiang, Yikun
collection PubMed
description SIMPLE SUMMARY: Protein arginine methyltransferases (PRMTs) are a group of enzymes that play pivotal roles in post-translational modifications (PTMs) and are involved in the regulation of various cellular processes. Although PRMTs are recognized for their impact on the development and prognosis of various cancers, their specific involvement in hepatocellular carcinoma (HCC) remains relatively limited. In this study, we systematically evaluated the association between PRMTs and HCC prognosis, revealing their potential as prognostic biomarkers. We also highlighted the importance of PRMT1 and elucidated its role in HCC progression, especially in the context of T cell exhaustion (Tex). Our study underscores the prospective utility of PRMTs, particularly PRMT1, as promising prognostic indicators for HCC, as well as therapeutic targets for this malignancy. ABSTRACT: HCC is a major contributor to cancer-related mortality worldwide. Curative treatments are available for a minority of patients diagnosed at early stages; however, only a few multikinase inhibitors are available and are marginally effective in advanced cases, highlighting the need for novel therapeutic targets. One potential target is the protein arginine methyltransferase, which catalyzes various forms of arginine methylation and is often overexpressed in various cancers. However, the diverse expression patterns and clinical values of PRMTs in HCC remain unclear. In the present study, we evaluated the transcriptional expression of PRMTs in HCC cohorts using publicly available datasets. Our results revealed a significant association between PRMTs and prognosis in HCC patients with diverse clinical characteristics and backgrounds. This highlights the promising potential of PRMTs as prognostic biomarkers in patients with HCC. In particular, single-cell RNA (scRNA) sequencing analysis coupled with another human cohort study highlighted the pivotal role of PRMT1 in HCC progression, particularly in the context of Tex. Translating these findings into specific therapeutic decisions may address the unmet therapeutic needs of patients with HCC.
format Online
Article
Text
id pubmed-10453297
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-104532972023-08-26 Integrative Evaluation of the Clinical Significance Underlying Protein Arginine Methyltransferases in Hepatocellular Carcinoma Jiang, Yikun Wei, Shibo Koo, Jin-Mo Kim, Hea-Ju Park, Wonyoung Zhang, Yan Guo, He Ha, Ki-Tae Oh, Chang-Myung Kang, Jong-Sun Jeong, Jee-Heon Ryu, Dongryeol Kim, Kyeong-Jin Jo, Yunju Cancers (Basel) Article SIMPLE SUMMARY: Protein arginine methyltransferases (PRMTs) are a group of enzymes that play pivotal roles in post-translational modifications (PTMs) and are involved in the regulation of various cellular processes. Although PRMTs are recognized for their impact on the development and prognosis of various cancers, their specific involvement in hepatocellular carcinoma (HCC) remains relatively limited. In this study, we systematically evaluated the association between PRMTs and HCC prognosis, revealing their potential as prognostic biomarkers. We also highlighted the importance of PRMT1 and elucidated its role in HCC progression, especially in the context of T cell exhaustion (Tex). Our study underscores the prospective utility of PRMTs, particularly PRMT1, as promising prognostic indicators for HCC, as well as therapeutic targets for this malignancy. ABSTRACT: HCC is a major contributor to cancer-related mortality worldwide. Curative treatments are available for a minority of patients diagnosed at early stages; however, only a few multikinase inhibitors are available and are marginally effective in advanced cases, highlighting the need for novel therapeutic targets. One potential target is the protein arginine methyltransferase, which catalyzes various forms of arginine methylation and is often overexpressed in various cancers. However, the diverse expression patterns and clinical values of PRMTs in HCC remain unclear. In the present study, we evaluated the transcriptional expression of PRMTs in HCC cohorts using publicly available datasets. Our results revealed a significant association between PRMTs and prognosis in HCC patients with diverse clinical characteristics and backgrounds. This highlights the promising potential of PRMTs as prognostic biomarkers in patients with HCC. In particular, single-cell RNA (scRNA) sequencing analysis coupled with another human cohort study highlighted the pivotal role of PRMT1 in HCC progression, particularly in the context of Tex. Translating these findings into specific therapeutic decisions may address the unmet therapeutic needs of patients with HCC. MDPI 2023-08-20 /pmc/articles/PMC10453297/ /pubmed/37627211 http://dx.doi.org/10.3390/cancers15164183 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Jiang, Yikun
Wei, Shibo
Koo, Jin-Mo
Kim, Hea-Ju
Park, Wonyoung
Zhang, Yan
Guo, He
Ha, Ki-Tae
Oh, Chang-Myung
Kang, Jong-Sun
Jeong, Jee-Heon
Ryu, Dongryeol
Kim, Kyeong-Jin
Jo, Yunju
Integrative Evaluation of the Clinical Significance Underlying Protein Arginine Methyltransferases in Hepatocellular Carcinoma
title Integrative Evaluation of the Clinical Significance Underlying Protein Arginine Methyltransferases in Hepatocellular Carcinoma
title_full Integrative Evaluation of the Clinical Significance Underlying Protein Arginine Methyltransferases in Hepatocellular Carcinoma
title_fullStr Integrative Evaluation of the Clinical Significance Underlying Protein Arginine Methyltransferases in Hepatocellular Carcinoma
title_full_unstemmed Integrative Evaluation of the Clinical Significance Underlying Protein Arginine Methyltransferases in Hepatocellular Carcinoma
title_short Integrative Evaluation of the Clinical Significance Underlying Protein Arginine Methyltransferases in Hepatocellular Carcinoma
title_sort integrative evaluation of the clinical significance underlying protein arginine methyltransferases in hepatocellular carcinoma
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10453297/
https://www.ncbi.nlm.nih.gov/pubmed/37627211
http://dx.doi.org/10.3390/cancers15164183
work_keys_str_mv AT jiangyikun integrativeevaluationoftheclinicalsignificanceunderlyingproteinargininemethyltransferasesinhepatocellularcarcinoma
AT weishibo integrativeevaluationoftheclinicalsignificanceunderlyingproteinargininemethyltransferasesinhepatocellularcarcinoma
AT koojinmo integrativeevaluationoftheclinicalsignificanceunderlyingproteinargininemethyltransferasesinhepatocellularcarcinoma
AT kimheaju integrativeevaluationoftheclinicalsignificanceunderlyingproteinargininemethyltransferasesinhepatocellularcarcinoma
AT parkwonyoung integrativeevaluationoftheclinicalsignificanceunderlyingproteinargininemethyltransferasesinhepatocellularcarcinoma
AT zhangyan integrativeevaluationoftheclinicalsignificanceunderlyingproteinargininemethyltransferasesinhepatocellularcarcinoma
AT guohe integrativeevaluationoftheclinicalsignificanceunderlyingproteinargininemethyltransferasesinhepatocellularcarcinoma
AT hakitae integrativeevaluationoftheclinicalsignificanceunderlyingproteinargininemethyltransferasesinhepatocellularcarcinoma
AT ohchangmyung integrativeevaluationoftheclinicalsignificanceunderlyingproteinargininemethyltransferasesinhepatocellularcarcinoma
AT kangjongsun integrativeevaluationoftheclinicalsignificanceunderlyingproteinargininemethyltransferasesinhepatocellularcarcinoma
AT jeongjeeheon integrativeevaluationoftheclinicalsignificanceunderlyingproteinargininemethyltransferasesinhepatocellularcarcinoma
AT ryudongryeol integrativeevaluationoftheclinicalsignificanceunderlyingproteinargininemethyltransferasesinhepatocellularcarcinoma
AT kimkyeongjin integrativeevaluationoftheclinicalsignificanceunderlyingproteinargininemethyltransferasesinhepatocellularcarcinoma
AT joyunju integrativeevaluationoftheclinicalsignificanceunderlyingproteinargininemethyltransferasesinhepatocellularcarcinoma